Shots: The four P-III ContRAst -1, 2, 3 & X studies will assess otilimab (90mg/150mg, SC, qw) vs PBO, tofacitinib (5mg, bid), sarilumab (200mg, SC) all in combination with MTX/ […]readmore
Tags : ContRAst Studies